Objective: The objective of the study was to evaluate the efficacy and tolerability of trimethoprim-sulfamethoxazole (also known as co-trimoxazole, TMPS) to treat Klebsiella pneumoniae (Kp)-K. pneumoniae carbapenemase (KPC) infections.
Methods: Clinical data of patients with a TMPS-susceptible Kp-KPC infection were collected as a case series.
Results: We report clinical outcomes and tolerability for 14 patients infected by Kp-KPC strains susceptible to TMPS, including three bloodstream infections. In ten cases (71.4%), TMPS was administered as monotherapy. In all but one case, Kp-KPC infection was cured. In the remaining patient, therapy was discontinued because of an adverse event.
Conclusions: The use of TMPS to treat TMPS-susceptible Kp-KPC infections seems promising.
Keywords: Carbapenemase; Co-trimoxazole; KPC; Multidrug-resistant infections; Trimethoprim–sulfamethoxazole.